Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...

Tobin Marcus, Wolfe Research policy and politics head, joins CNBC's 'Squawk Box' to discuss what Trump's pick for HHS ...

Wolfe Research initiated coverage of BioMarin (BMRN) with an Outperform rating and $95 price target With limited downside risk following ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...

Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

As of October 22, 2024, the average one-year price target for AbbVie is $205.97/share. The forecasts range from a low of $171.70 to a high of $236.25. The average price target represents an ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Eli Lilly and (SNSE:LLYCL) with a Outperform recommendation. There are 5,242 funds or institutions reporting ...